Template:ST elevation myocardial infarction: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Tarek Nafee (talk | contribs) No edit summary |
||
| (16 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue" | {| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue" | ||
|- bgcolor="LightGrey" | |||
! | |||
[[Acute coronary syndrome|Acute Coronary Syndrome Main Page]] | |||
|- | |||
! | |||
|- | |- | ||
| colspan="1" style="text-align:center; background:DarkGray" | | | colspan="1" style="text-align:center; background:DarkGray" | | ||
'''ST | '''ST Elevation Myocardial Infarction Microchapters''' | ||
|- bgcolor="LightGrey" | |- bgcolor="LightGrey" | ||
! | ! | ||
| Line 91: | Line 97: | ||
! | ! | ||
[[ST elevation myocardial infarction risk stratification and prognosis|Risk Stratification and Prognosis]] | [[ST elevation myocardial infarction risk stratification and prognosis|Risk Stratification and Prognosis]] | ||
|- | |||
! | |||
|- bgcolor="Pink" | |||
! | |||
[[ST elevation myocardial infarction in pregnancy|Pregnancy]] | |||
|- | |- | ||
! | ! | ||
| Line 187: | Line 199: | ||
::[[ST elevation myocardial infarction reperfusion therapy|Reperfusion Therapy (Overview of Fibrinolysis and Primary PCI)]] | ::[[ST elevation myocardial infarction reperfusion therapy|Reperfusion Therapy (Overview of Fibrinolysis and Primary PCI)]] | ||
::[[ST elevation myocardial infarction fibrinolytic therapy|Fibrinolysis]] | ::[[ST elevation myocardial infarction fibrinolytic therapy|Fibrinolysis]] | ||
:::[[ST elevation myocardial infarction fibrinolysis| Reperfusion at a Non–PCI-Capable Hospital:Recommendations]] | |||
:Mechanical Reperfusion | :Mechanical Reperfusion | ||
::[[Door-to-balloon|The importance of reducing Door-to-Balloon times]] | ::[[Door-to-balloon|The importance of reducing Door-to-Balloon times]] | ||
::[[ST elevation myocardial infarction primary percutaneous coronary intervention|Primary PCI]] | ::[[ST elevation myocardial infarction primary percutaneous coronary intervention|Primary PCI]] | ||
::Adjunctive and Rescue PCI | ::[[ST elevation myocardial infarction percutaneous coronary intervention following fibrinolytic administration|Adjunctive and Rescue PCI]] | ||
::Rescue PCI | ::[[ST elevation myocardial infarction rescue percutaneous coronary intervention|Rescue PCI]] | ||
::Facilitated PCI | ::[[ST elevation myocardial infarction facilitated percutaneous coronary intervention|Facilitated PCI]] | ||
::Adjunctive PCI | ::[[ST elevation myocardial infarction adjunctive percutaneous coronary intervention|Adjunctive PCI]] | ||
::CABG | ::[[ST elevation myocardial infarction coronary artery bypass grafting|CABG]] | ||
::Management of Patients Who Were Not Reperfused | ::[[ST elevation myocardial infarction management of patients who were not reperfused|Management of Patients Who Were Not Reperfused]] | ||
::Assessing Success of Reperfusion | ::[[ST elevation myocardial infarction assessing success of reperfusion|Assessing Success of Reperfusion]] | ||
:Antithrombin Therapy | :Antithrombin Therapy | ||
::Antithrombin therapy | ::[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy|Antithrombin therapy]] | ||
::Unfractionated heparin | ::[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Unfractionated Heparin|Unfractionated heparin]] | ||
::Low Molecular Weight Heparinoid Therapy | ::[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Enoxaparin|Low Molecular Weight Heparinoid Therapy]] | ||
::Direct Thrombin Inhibitor Therapy | ::[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Bivalirudin|Direct Thrombin Inhibitor Therapy]] | ||
::Factor Xa Inhibition | ::[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Fondaparinux|Factor Xa Inhibition]] | ||
::DVT prophylaxis | ::[[ST elevation myocardial infarction deep vein thrombosis prophylaxis and anticoagulation|DVT prophylaxis]] | ||
::Long term anticoagulation | ::[[ST elevation myocardial infarction deep vein thrombosis prophylaxis and anticoagulation|Long term anticoagulation]] | ||
:Antiplatelet Agents | :Antiplatelet Agents | ||
::Aspirin | ::[[ST elevation myocardial infarction aspirin therapy|Aspirin]] | ||
::Thienopyridine Therapy | ::[[ST elevation myocardial infarction thienopyridine therapy|Thienopyridine Therapy]] | ||
::Glycoprotein IIbIIIa Inhibition | ::[[ST elevation myocardial infarction glycoprotein IIbIIIa inhibition|Glycoprotein IIbIIIa Inhibition]] | ||
:Other Initial Therapy | :Other Initial Therapy | ||
::Inhibition of the Renin-Angiotensin-Aldosterone System | ::[[ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge|Inhibition of the Renin-Angiotensin-Aldosterone System]] | ||
::Magnesium Therapy | ::[[ST elevation myocardial infarction magnesium therapy|Magnesium Therapy]] | ||
::Glucose Control | ::[[ST elevation myocardial infarction glucose control|Glucose Control]] | ||
::Calcium Channel Blocker Therapy | ::[[ST elevation myocardial infarction calcium channel blocker therapy|Calcium Channel Blocker Therapy]] | ||
::Lipid Management | ::[[ST elevation myocardial infarction lipid management|Lipid Management]] | ||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
[[ST elevation myocardial infarction discharge care|Pre-Discharge Care]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
[[Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT|Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT]] | |||
|- | |- | ||
! | ! | ||
| Line 220: | Line 243: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
[[ST elevation myocardial infarction | [[ST elevation myocardial infarction Post Hospitalization|Post Hospitalization Plan of Care]] | ||
|- | |- | ||
! | ! | ||
| Line 227: | Line 250: | ||
! | ! | ||
[[ST elevation myocardial infarction secondary prevention|Long-Term Medical Therapy and Secondary Prevention]] | [[ST elevation myocardial infarction secondary prevention|Long-Term Medical Therapy and Secondary Prevention]] | ||
:Overview | :[[ST elevation myocardial infarction secondary prevention|Overview]] | ||
:Inhibition of the Renin-Angiotensin-Aldosterone System | :[[ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge|Inhibition of the Renin-Angiotensin-Aldosterone System]] | ||
:Cardiac Rehabilitation | :[[ST elevation myocardial infarction cardiac rehabilitation|Cardiac Rehabilitation]] | ||
:Pacemaker Implantation | :[[ST elevation myocardial infarction pacemaker implantation|Pacemaker Implantation]] | ||
:Long Term Anticoagulation | :[[ST elevation myocardial infarction deep vein thrombosis prophylaxis and anticoagulation|Long Term Anticoagulation]] | ||
:[[ST elevation myocardial infarction implantable cardioverter defibrillator|Implantable Cardioverter Defibrillator]] | |||
:[[ICD implantation within 40 days of myocardial infarction]] | |||
:[[ICD within 90 days of revascularization]] | |||
|- | |- | ||
Latest revision as of 00:11, 4 March 2017
|
ST Elevation Myocardial Infarction Microchapters |
|
Differentiating ST elevation myocardial infarction from other Diseases |
|
Diagnosis |
|
Treatment |
|
|
Case Studies |
|
ST elevation myocardial infarction On the Web |
|
Directions to Hospitals Treating ST elevation myocardial infarction |
|
Risk calculators and risk factors for ST elevation myocardial infarction |